Skip to main content
Signal8
Launch Terminal

Outlook Therapeutics, Inc. (OTLK)

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc.

NASDAQ:OTLKHealthcare
-5.15%$0.4681
AH$0.4741+1.28%vs close
Mkt Cap$113.96M
Float204.15M
O/S243.45M
Vol
$ Vol
RVOL
Inst Own8.3%
SI16.0%
Earnings
Dilution
Outlook Therapeutics, Inc. logoNASDAQ:OTLK$0.4681-5.15%
Phase Distribution
5 lead-sponsored trials·1 active·4 completed
Phase 35
Status Overview
Active, not recruiting1
Completed4

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
  • Phase 3
    Completed

    A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

    bevacizumab, ranibizumab

    Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration +1

    Enrollment
    228
    Start
    Jun 2019
    Primary Completion
    Jun 2021
    Completion
    Jul 2021
    NCT03834753
  • Phase 3
    Completed

    A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

    bevacizumab, ranibizumab

    Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration +1

    Enrollment
    61
    Start
    Oct 2018
    Primary Completion
    Jul 2020
    Completion
    Aug 2020
    NCT03844074
  • Phase 3
    Completed

    A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

    bevacizumab

    Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration +3

    Enrollment
    197
    Start
    Oct 2020
    Primary Completion
    Feb 2021
    Completion
    Feb 2021
    NCT04516278
  • Phase 3
    Active, not recruiting

    A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders

    bevacizumab

    Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration +3

    Enrollment
    120
    Start
    Nov 2021
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2027est.
    NCT05112861
  • Phase 3
    Completed

    A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

    bevacizumab, ranibizumab

    Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration +1

    Enrollment
    400
    Start
    Jan 2024
    Primary Completion
    Nov 2024
    Completion
    Dec 2024
    NCT06190093
Search ClinicalTrials.gov for “Outlook Therapeutics”